Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model

Sakura Yamamoto, Jun Wada, Takane Katayama, Takumi Jikimoto, Masakuni Nakamura, Shohiro Kinoshita, Kyung-Mi Lee, Masato Kawabata, Toshiro Shirakawa

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5×10 7 CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum, or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0×10 7 CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity.

Original languageEnglish
Pages (from-to)6684-6691
Number of pages8
JournalVaccine
Volume28
Issue number41
DOIs
Publication statusPublished - 2010 Sep 1

Fingerprint

typhoid fever
Bifidobacterium
Typhoid Fever
Salmonella typhimurium
Salmonella Typhimurium
Salmonella
Bifidobacterium longum
Vaccines
vaccines
antigens
Antigens
mice
Typhoid-Paratyphoid Vaccines
Inbred BALB C Mouse
Flagellin
Mucosal Immunity
mucosal immunity
flagellin
Immunization
mouth

Keywords

  • Bifidobacterium
  • Mucosal vaccine
  • Salmonella

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model. / Yamamoto, Sakura; Wada, Jun; Katayama, Takane; Jikimoto, Takumi; Nakamura, Masakuni; Kinoshita, Shohiro; Lee, Kyung-Mi; Kawabata, Masato; Shirakawa, Toshiro.

In: Vaccine, Vol. 28, No. 41, 01.09.2010, p. 6684-6691.

Research output: Contribution to journalArticle

Yamamoto, Sakura ; Wada, Jun ; Katayama, Takane ; Jikimoto, Takumi ; Nakamura, Masakuni ; Kinoshita, Shohiro ; Lee, Kyung-Mi ; Kawabata, Masato ; Shirakawa, Toshiro. / Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model. In: Vaccine. 2010 ; Vol. 28, No. 41. pp. 6684-6691.
@article{9eb6f65f88694a8f8221ea8e85d19cd9,
title = "Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model",
abstract = "We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5×10 7 CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum, or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0×10 7 CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity.",
keywords = "Bifidobacterium, Mucosal vaccine, Salmonella",
author = "Sakura Yamamoto and Jun Wada and Takane Katayama and Takumi Jikimoto and Masakuni Nakamura and Shohiro Kinoshita and Kyung-Mi Lee and Masato Kawabata and Toshiro Shirakawa",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.vaccine.2010.08.007",
language = "English",
volume = "28",
pages = "6684--6691",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "41",

}

TY - JOUR

T1 - Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model

AU - Yamamoto, Sakura

AU - Wada, Jun

AU - Katayama, Takane

AU - Jikimoto, Takumi

AU - Nakamura, Masakuni

AU - Kinoshita, Shohiro

AU - Lee, Kyung-Mi

AU - Kawabata, Masato

AU - Shirakawa, Toshiro

PY - 2010/9/1

Y1 - 2010/9/1

N2 - We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5×10 7 CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum, or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0×10 7 CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity.

AB - We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5×10 7 CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum, or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0×10 7 CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity.

KW - Bifidobacterium

KW - Mucosal vaccine

KW - Salmonella

UR - http://www.scopus.com/inward/record.url?scp=77956494584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956494584&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.08.007

DO - 10.1016/j.vaccine.2010.08.007

M3 - Article

C2 - 20709009

AN - SCOPUS:77956494584

VL - 28

SP - 6684

EP - 6691

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 41

ER -